“…Designing de novo proteins using Rosetta has successfully provided many robust proteins with diverse topologies for various protein engineering purposes, including small molecule binding (Dou et al., 2018; Tinberg et al., 2013), therapeutic developments (Cao et al., 2020; Fleishman et al., 2011; Silva et al., 2019), orthogonal biological signaling system construction (Chen et al., 2019; Langan et al., 2019; Quijano‐Rubio et al., 2020), and material formation (Hsia et al., 2020; Pyles, Zhang, De Yoreo, & Baker, 2019; Ueda et al., 2020). A number of de novo proteins designed for the abovementioned applications have significantly different secondary structure features, and were generated using a similar pipeline, which all involved the key step of using the structure modifier in Rosetta, the blueprint builder (Huang et al., 2011; Marcos et al., 2018).…”